KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $226.5 million.

  • Acadia Pharmaceuticals' Income from Continuing Operations rose 119.14% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 103.33%. This contributed to the annual value of $226.5 million for FY2024, which is 469.20% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $226.5 million for FY2024, which was up 469.20% from -$61.3 million recorded in FY2023.
  • Acadia Pharmaceuticals' 5-year Income from Continuing Operations high stood at $226.5 million for FY2024, and its period low was -$281.6 million during FY2020.
  • For the 3-year period, Acadia Pharmaceuticals' Income from Continuing Operations averaged around -$17.0 million, with its median value being -$61.3 million (2023).
  • Per our database at Business Quant, Acadia Pharmaceuticals' Income from Continuing Operations decreased by 28.66% in 2022 and then spiked by 469.20% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$281.6 million in 2020, then soared by 40.38% to -$167.9 million in 2021, then decreased by 28.66% to -$216.0 million in 2022, then spiked by 71.60% to -$61.3 million in 2023, then skyrocketed by 469.20% to $226.5 million in 2024.